Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma

Toshihide Kawai, Hiroshi Hirose, Yoshiko Seto, Haruhisa Fujita, Hiroshi Fujita, Kaname Ukeda, Takao Saruta

研究成果: Article査読

19 被引用数 (Scopus)


To elucidate the mechanisms by which troglitazone, which is a direct ligand for peroxisome proliferator-activated receptor (PPAR) gamma, ameliorates insulin resistance, we have demonstrated that PPAR gamma is expressed in a pancreatic beta cell line, INS-1, using reverse transcription-polymerase chain reaction (RT-PCR). We incubated the cells with 5 μmol/l troglitazone and 1 mmol/l of each major free fatty acid (FFA; palmitic acid, oleic acid, and linoleic acid), alone or in combination, for 48 h. After that, we evaluated glucose-stimulated insulin secretion (GSIS) and 25 mmol/l KCl-induced insulin secretion in the presence of diazoxide, which clamps membrane potential. Our results showed: (1) treatment with troglitazone for 48 h caused enhancement of GSIS, although troglitazone significantly suppressed cell viability assessed by MTT assay. (2) In cells co-treated with troglitazone and FFA, troglitazone ameliorated lipotoxicity due to FFA. (3) In the presence of 300 μmol/l diazoxide and 25 mmol/l KCl, troglitazone did not affect the recovery of GSIS in INS-1 cells. These results suggest that insulin secretion from the rat insulinoma cell line, INS-1, is modulated by troglitazone, acting somewhere in the ATP-sensitive K+ channel pathway, possibly through PPAR gamma.

ジャーナルDiabetes Research and Clinical Practice
出版ステータスPublished - 2002

ASJC Scopus subject areas

  • 内科学
  • 内分泌学、糖尿病および代謝内科学
  • 内分泌学


「Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。